TARGIMMUNE THERAPEUTICS AG has a total of 26 patent applications. Its first patent ever was published in 2009. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and biotechnology are AKSHAYA BIO INC, CODIAK BIOSCIENCES INC and NANJING KAEDI BIOTECH INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Australia | 3 | |
#5 | Canada | 2 | |
#6 | Brazil | 1 | |
#7 | China | 1 | |
#8 | Hungary | 1 | |
#9 | Israel | 1 | |
#10 | Japan | 1 | |
#11 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Levitzki Alexander | 18 |
#2 | Shir Alexei | 15 |
#3 | Langut Yael | 15 |
#4 | Zigler Maya | 12 |
#5 | Kitas Eric | 7 |
#6 | Pombo-Villar Esteban | 7 |
#7 | Talhami Alaa | 5 |
#8 | Levitzki Alex | 5 |
#9 | Joubran Salim | 5 |
#10 | Friedman Lital | 4 |
Publication | Filing date | Title |
---|---|---|
WO2020201568A1 | Immunotherapy for the treatment of cancer | |
WO2019170899A1 | A vector for the expression of cetuximab antibody chains | |
WO2019170890A1 | A recombinant protein comprising a double stranded rna binding domain | |
EP3688008A1 | Castration resistant prostate cancer | |
CA3034989A1 | Chimeric proteins for targeting dsrna | |
EP3705493A1 | Egfr-homing double-stranded rna vector for systemic cancer treatment |